Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK

Roche

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02658747

ML30033

Details and patient eligibility

About

This is a multi-center retrospective observational research study collecting data for participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) up to 6 years before start of data collection and who have completed/stopped docetaxel treatment at least 30 days prior to data collection. The primary goal of this study is to describe the percentage of participants with at least one neutropenic sepsis (NS) episode following initiation of treatment with single-agent docetaxel. Data will be collected until end of docetaxel treatment plus an additional 30 days to allow for presentation with toxicity.

Enrollment: 120 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with locally advanced or metastatic (stage Ill or IV) non-small cell lung cancer (NSCLC)
• Relapsed disease following, or unable to tolerate, at least one line of prior chemotherapy
• Initiated on single-agent docetaxel up to a maximum of 6 years prior to date of collection
• Aged 18 years at date of first docetaxel dose
• Completed or stopped treatment with docetaxel at least 30 days prior to date of data collection

Exclusion criteria

• Receiving docetaxel in an interventional clinical trial
• For whom no details of absolute neutrophil count are recorded

Trial design

120 participants in 1 patient group

Cohort Docetaxel

Description:

Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)

Treatment:

Other: No intervention